Pharmacognosy, Biotechnology, and Biologic Medicines
What the domain tests
This domain spans natural-product drugs and modern biologics: source organisms, active constituents, extraction, biosynthetic production, monoclonal antibodies, vaccines, biosimilars, immunogenicity, and cold-chain handling. The exam may ask you to distinguish a biologic from a small molecule or to explain why biosimilars are not automatic generics.
Core rules and concepts
- Many classic drugs derive from plants or microorganisms: digoxin from Digitalis lanata, morphine from Papaver somniferum, paclitaxel from Taxus species, penicillin from Penicillium molds.
- Biologics are produced in living systems and are large, structurally complex, and sensitive to manufacturing changes. Monoclonal antibodies, insulin analogues, erythropoietins, and vaccines are examples.
- Biosimilars must demonstrate comparability to a reference biologic in quality, safety, and efficacy; they are not identical copies. Immunogenicity is a special concern because even small structural differences can trigger anti-drug antibodies.
- Cold chain and handling matter: many biologics require specific temperature ranges, protection from light, and avoidance of shaking or freezing.
- Pharmacognosy also includes quality issues: plant identity, adulteration, variable alkaloid content, and contamination.
Worked example
A patient asks whether a biosimilar infliximab is “the same as the original.” The correct explanation is that a biosimilar has been shown to be highly similar and comparable in efficacy and safety, but it is not structurally identical. The reasoning: biologics are made in living cells, so manufacturing differences can affect glycosylation and immunogenicity; regulatory approval requires comparability data. The trap is calling a biosimilar a generic, which applies to chemically identical small molecules.
Traps that cost marks
Do not assume all natural products are safe because they are “natural.” Do not describe biosimilars as exact copies. Do not ignore cold-chain deviation when a biologic looks cloudy or was left out. Do not confuse the source plant with the active constituent without verification.
Key points
- Digoxin comes from Digitalis lanata; morphine from opium poppy.
- Biologics are complex products made in living systems.
- Biosimilars are comparable, not identical, to reference biologics.
- Immunogenicity is a key biologic safety concern.
- Cold-chain and handling deviations can ruin biologic activity.